Biotech’s newborn unicorn Sana grabs Harvard tech aimed at slipping engineered stem cells...

[cafead]

via After leading one of the early pioneers in customized cancer therapies using patient cells for CAR-T, the founding execs at Sana Biotechnology are now nailing down the IP for a new generation of off-the-shelf cell therapies that they believe can have built-in protection against an immune response.

article source